Geron move to settle stem cell suit marks shift
Geron's decision to give up commercialisation rights to all but three embryonic stem cell types marks a sharpened focus on drug development in what has become an industry-wide trend. Patents have no
Geron's decision to give up commercialisation rights to all but three embryonic stem cell types marks a sharpened focus on drug development in what has become an industry-wide trend. Patents have no